Hester Bios
Hester Bios Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
1 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
Hester Biosciences aims for holistic disease prevention by combining vaccines with biosecurity, hygiene, and health products, enhancing cross-selling opportunities, particularly in poultry. Revenue growth driven by deeper market penetration in poultry healthcare and expansion of poultry health products portfolio.
From Hester Bios's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Hester Biosciences aims for holistic disease prevention by combining vaccines with biosecurity, hygiene, and health products, enhancing cross-selling opportunities, particularly in poultry.
- Poultry segment growth driven by deeper market penetration, scientific field engagement, and expanded health product portfolio; higher market share contributing to revenue increase.
- Animal vaccine business relies on planned preventive vaccination schedules rather than outbreak-driven sudden demand; government immunization programs expected to support steady demand.
- Africa and Nepal markets hold significant growth potential, especially with local manufacturing facilities; Africa considered a promising but volatile new territory.
- Capacity utilization around 60-65% with recent addition of fill-and-finish and BSL3 facilities, indicating room for growth without immediate new capacity.
- Pet care division is emerging, with ongoing expansion and investment; vaccines in this segment are under development with no near-term launch guidance.
- Overall, management expects steady growth driven by market expansion, new product introductions, and enhanced distribution networks over next 1-2 years.
Profitability & Margins
See what Hester Bios said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Recent capital expenditure includes the commissioning of a new BSL3 facility and fill-and-finish capacity, with fixed assets increasing by around Rs. 200 crore in FY'26.
- The BSL3 facility, initially built for human vaccine efforts, is now being repurposed to support veterinary product manufacturing.
- Current capacity utilization is around 60-65%, including the new facilities, with efforts ongoing to optimize manufacturing output.
- No specific future capex guidance provided; focus remains on maximizing existing manufacturing infrastructure.
- Investments continue in research and development, especially biologics, with regulatory dossiers submitted to expand the biological pipeline.
- Strategic emphasis is on strengthening biological portfolios, market penetration, and international market development (Nepal, Africa).
- No explicit mention of upcoming large-scale capex, indicating a near-term focus on operational excellence and existing asset utilization.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Hester Bios said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Hester Bios — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹100 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Hester Biosciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Hester Bios Q1 FY27 results?
Hester Biosciences aims for holistic disease prevention by combining vaccines with biosecurity, hygiene, and health products, enhancing cross-selling opportunities, particularly in poultry. Revenue growth driven by deeper market penetration in poultry healthcare and expansion of poultry health products portfolio.
What is Hester Bios share price analysis?
Hester Bios currently shows a below-average growth signal. The stock trades at a P/E of 37.9 with a market cap of ₹2,014 Cr. Investors should review the full earnings analysis for detailed insights.
Is Hester Bios planning capital expenditure?
Recent capital expenditure includes the commissioning of a new BSL3 facility and fill-and-finish capacity, with fixed assets increasing by around Rs.
Keep Hester Bios on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.